Vaxart Deferred Long Term Liab from 2010 to 2024
| VXRT Stock | USD 0.61 0.01 1.67% |
Deferred Long Term Liabilities | First Reported 2011-06-30 | Previous Quarter 14.3 M | Current Value 14.4 M | Quarterly Volatility 12.6 M |
Check Vaxart financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vaxart's main balance sheet or income statement drivers, such as Depreciation And Amortization of 9.1 M, Interest Expense of 1.4 M or Total Revenue of 7 M, as well as many indicators such as Price To Sales Ratio of 10.68, Dividend Yield of 0.0 or PTB Ratio of 2.34. Vaxart financial statements analysis is a perfect complement when working with Vaxart Valuation or Volatility modules.
Vaxart | Deferred Long Term Liab |
Latest Vaxart's Deferred Long Term Liab Growth Pattern
Below is the plot of the Deferred Long Term Liab of Vaxart Inc over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. Vaxart's Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vaxart's overall financial position and show how it may be relating to other accounts over time.
| Deferred Long Term Liab | 10 Years Trend |
|
Deferred Long Term Liab |
| Timeline |
Vaxart Deferred Long Term Liab Regression Statistics
| Arithmetic Mean | 14,102,313 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 68.72 | |
| Mean Deviation | 5,976,782 | |
| Median | 14,413,000 | |
| Standard Deviation | 9,691,598 | |
| Sample Variance | 93.9T | |
| Range | 32.8M | |
| R-Value | (0.15) | |
| Mean Square Error | 98.8T | |
| R-Squared | 0.02 | |
| Significance | 0.59 | |
| Slope | (331,510) | |
| Total Sum of Squares | 1315T |
Vaxart Deferred Long Term Liab History
About Vaxart Financial Statements
Vaxart shareholders use historical fundamental indicators, such as Deferred Long Term Liab, to determine how well the company is positioned to perform in the future. Although Vaxart investors may analyze each financial statement separately, they are all interrelated. The changes in Vaxart's assets and liabilities, for example, are also reflected in the revenues and expenses on on Vaxart's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Deferred Long Term Liabilities | 13 M | 12.7 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Vaxart Stock Analysis
When running Vaxart's price analysis, check to measure Vaxart's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxart is operating at the current time. Most of Vaxart's value examination focuses on studying past and present price action to predict the probability of Vaxart's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxart's price. Additionally, you may evaluate how the addition of Vaxart to your portfolios can decrease your overall portfolio volatility.